Cargando…

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

BACKGROUND: Determining how prior immune checkpoint inhibitor (ICI) therapy influences outcomes in cancer patients presenting with COVID‐19 is essential for patient management but must account for confounding variables. METHODS: We performed a systematic review and meta‐analysis of studies reporting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minkove, Samuel J., Sun, Junfeng, Li, Yan, Cui, Xizhong, Cooper, Diane, Eichacker, Peter Q., Torabi‐Parizi, Parizad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111045/ https://www.ncbi.nlm.nih.gov/pubmed/35416370 http://dx.doi.org/10.1002/rmv.2352

Ejemplares similares

Effect of low-to-moderate hyperoxia on lung injury in preclinical animal models: a systematic review and meta-analysis
por: Minkove, Samuel, et al.
Publicado: (2023)

Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis
por: Busch, Lindsay M., et al.
Publicado: (2020)

Increased body mass index and adjusted mortality in ICU patients with sepsis or septic shock: a systematic review and meta-analysis
por: Pepper, Dominique J., et al.
Publicado: (2016)

A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results
por: Xu, Wanying, et al.
Publicado: (2017)

Correction: A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results
por: Xu, Wanying, et al.
Publicado: (2017)

The Role of Semaphorins and Their Receptors in Innate Immune Responses and Clinical Diseases of Acute Inflammation
por: Kanth, Shreya M., et al.
Publicado: (2021)

The Effects of Obesity on Outcome in Preclinical Animal Models of Infection and Sepsis: A Systematic Review and Meta-Analysis
por: Xu, Wanying, et al.
Publicado: (2020)

Comparison of survivors and nonsurvivors in 27 confirmed injectional anthrax cases from the 2009 outbreak in Scotland
por: Booth, M, et al.
Publicado: (2013)

Network representations of immune system complexity
por: Subramanian, Naeha, et al.
Publicado: (2015)

Ethical and Practical Considerations in Providing Critical Care to Patients With Ebola Virus Disease
por: Torabi-Parizi, Parizad, et al.
Publicado: (2015)

B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components
por: Remy, Kenneth E, et al.
Publicado: (2013)

The Potential Pathogenic Contributions of Endothelial Barrier and Arterial Contractile Dysfunction to Shock Due to B. anthracis Lethal and Edema Toxins
por: Suffredini, Dante A., et al.
Publicado: (2017)

Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies
por: Altaweel, Laith, et al.
Publicado: (2009)

A Review of the Efficacy of FDA-Approved B. anthracis Anti-Toxin Agents When Combined with Antibiotic or Hemodynamic Support in Infection- or Toxin-Challenged Preclinical Models
por: Couse, Zoe, et al.
Publicado: (2021)

Hydrocortisone decreases lethality and inflammatory cytokine and nitric oxide production in rats challenged with B. anthracis cell wall peptidoglycan
por: Li, Yan, et al.
Publicado: (2020)

The Potential Contributions of Lethal and Edema Toxins to the Pathogenesis of Anthrax Associated Shock
por: Hicks, Caitlin W., et al.
Publicado: (2011)

Anthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support
por: Suffredini, Dante A., et al.
Publicado: (2017)

Medical Guidelines and Performance Measures: The Need to Keep Them Free of Industry Influence
por: Eichacker, Peter Q., et al.
Publicado: (2008)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical Studies
por: Suffredini, Dante A., et al.
Publicado: (2015)

Immune checkpoint inhibitor-induced colitis: A comprehensive review
por: Som, Aniruddh, et al.
Publicado: (2019)

Biomarkers for Immune Checkpoint Inhibitor–Induced Myocarditis: Caution Needed
por: Jaffe, Allan S.
Publicado: (2022)

Raxibacumab augments hemodynamic support and improves outcomes during shock with B. anthracis edema toxin alone or together with lethal toxin in canines
por: Remy, Kenneth E, et al.
Publicado: (2015)

Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
por: Lee, Seon-Mi, et al.
Publicado: (2023)

Purified cell wall from the probiotic bacterium Lactobacillus gasseri activates systemic inflammation and, at higher doses, produces lethality in a rat model
por: Xu, Xinhui, et al.
Publicado: (2014)

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
por: Cui, Xizhong, et al.
Publicado: (2017)

Checkpoint inhibitors: What gastroenterologists need to know
por: Ahmed, Monjur
Publicado: (2018)

Isolated Gastritis Secondary to Immune Checkpoint Inhibitors Complicated by Superimposed Cytomegalovirus Infection
por: Nguyen, Anita H., et al.
Publicado: (2022)

Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
por: Li, Xinya, et al.
Publicado: (2023)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
por: Rosner, Samuel, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis
por: Noori, Maryam, et al.
Publicado: (2023)

Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review
por: Mallio, Carlo Augusto, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
por: Nguyen, Lee S, et al.
Publicado: (2022)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
por: Wu, Qinghua, et al.
Publicado: (2022)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
por: Hommes, Josefien W., et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II
por: Bukamur, Hazim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q869qa6sq0070fogr05dnabuqs